Market News AIOpen the app

Eikon Therapeutics got the green light from the FDA to start testing EIK1006 on prostate cancer patients.

TrialRead the original at globenewswire.com
Good for EIKN

Eikon received FDA clearance to move EIK1006 into a human study. This advances testing, but dosing and the first results are still expected in 2027.

EIKN · Eikon Therapeutics, Inc.

AI read · Good for EIKN

The AI's read

This gives Eikon a chance to test its prostate cancer drug in people. The drug is designed to target receptor forms linked to resistance to older hormone treatments. The study has not started, and there are no patient results yet.

Get alerts for EIKN

Follow Eikon Therapeutics, Inc. (EIKN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EIKN
Free on the App Store and Google Play, or on the web.